Moody National Bank Trust Division Makes New Investment in GRAIL, Inc. $GRAL

Moody National Bank Trust Division purchased a new position in shares of GRAIL, Inc. (NASDAQ:GRAL) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 13,300 shares of the company’s stock, valued at approximately $908,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Farallon Capital Management LLC grew its position in GRAIL by 73.7% in the fourth quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company’s stock valued at $200,510,000 after purchasing an additional 993,684 shares in the last quarter. Baker BROS. Advisors LP increased its stake in GRAIL by 27.9% in the 4th quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock valued at $178,484,000 after buying an additional 455,208 shares during the last quarter. Vanguard Group Inc. lifted its position in GRAIL by 9.0% during the 4th quarter. Vanguard Group Inc. now owns 1,980,783 shares of the company’s stock worth $169,535,000 after buying an additional 163,790 shares in the last quarter. State Street Corp lifted its position in GRAIL by 38.8% during the 4th quarter. State Street Corp now owns 1,827,523 shares of the company’s stock worth $156,418,000 after buying an additional 510,546 shares in the last quarter. Finally, Morgan Stanley boosted its stake in shares of GRAIL by 63.8% during the 4th quarter. Morgan Stanley now owns 1,511,687 shares of the company’s stock worth $129,385,000 after buying an additional 588,647 shares during the last quarter.

GRAIL News Roundup

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: Revenue and earnings beat expectations: GRAIL reported second-quarter revenue of $44.7 million, above the $42.4 million consensus estimate, while its adjusted loss of $2.56 per share was $0.10 better than expected. GRAIL quarterly earnings report
• Positive Sentiment: Galleri commercial momentum remained strong: Second-quarter Galleri test volume increased 35% year over year to more than 61,000 tests, while Galleri revenue rose 24% to $42.6 million. For the first half, test volume grew 42% and revenue increased 30%. GRAIL Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Clinical progress and additional capital: GRAIL cited favorable NHS-Galleri and PATHFINDER 2 results presented at the 2026 ASCO meeting and completed a $110 million equity financing with Samsung. The funding strengthens liquidity for commercialization and research, although it may increase share count. GRAIL clinical results and financing announcement
• Neutral Sentiment: Profitability remains distant: Despite the revenue and EPS beats, GRAIL continues to operate at a substantial loss, with a negative net margin of 253.22% and analysts expecting a full-year loss of approximately $10.91 per share. GRAIL financial information
• Negative Sentiment: Ongoing securities litigation adds risk: Multiple law firms publicized a class-action lawsuit involving GRAIL and solicited investors to seek lead-plaintiff status. The announcements could weigh on sentiment and create potential legal costs or liabilities, although they do not represent a court finding against the company. Portnoy Law Firm class-action announcement

Insider Activity

In other news, insider Andrew John Partridge sold 1,491 shares of GRAIL stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $61.08, for a total transaction of $91,070.28. Following the completion of the transaction, the insider directly owned 163,738 shares in the company, valued at approximately $10,001,117.04. The trade was a 0.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.83% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on GRAL. Wolfe Research initiated coverage on GRAIL in a report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. The Goldman Sachs Group started coverage on GRAIL in a report on Friday, June 5th. They set a “neutral” rating and a $60.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research note on Friday, July 17th. Robert W. Baird set a $70.00 price target on GRAIL in a research note on Wednesday, May 6th. Finally, TD Cowen reaffirmed a “buy” rating on shares of GRAIL in a research report on Wednesday, July 15th. Four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, GRAIL currently has a consensus rating of “Hold” and a consensus target price of $67.78.

GRAIL Stock Performance

Shares of GRAL stock opened at $74.18 on Thursday. GRAIL, Inc. has a 52-week low of $29.95 and a 52-week high of $118.84. The stock has a market cap of $3.18 billion, a price-to-earnings ratio of -7.15 and a beta of 3.24. The firm’s 50-day moving average is $66.97 and its 200-day moving average is $66.72.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.10. The business had revenue of $44.69 million during the quarter, compared to analysts’ expectations of $42.39 million. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%. Sell-side analysts predict that GRAIL, Inc. will post -10.91 EPS for the current fiscal year.

GRAIL Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.